Lacroix et al have published new research revealing the presence of HHV-6B in the Reed Sternberg cells of patients with nodular sclerosis Hodgkin’s lymphoma…
HHV-6 status determines effectiveness of interferon treatment in Multiple Sclerosis
The administration of immune agents to patients (known as Interferon-Beta-1b, or IFN-beta, therapy) has been widely used in the treatment and maintenance of multiple sclerosis (MS). Additionally, it is known that the risk of MS exacerbation is much higher in patients with active HHV-6 infection than in patients with a latent infection of the virus (Lafuente 2006, 2007; Chapenko 2003). …
7th International Conference on HHV-6 & HHV-7 held February 27-March 2, 2011
Over 120 researchers and clinicians from 18 countries gathered in Reston, Virginia. Work was presented on the most recent implications and findings of HHV-6 in a broad spectrum of research and clinical settings.
HHV-6 uses novel form of latency
HHV-6 integrates into the chromosome during latency and reactivates in response to chemical stimulation.
Dr. Asano Receives 2011 Lifetime Achievement Award
Dr. Yoshizo Asano was presented the Dharam Ablashi Lifetime Achievement Award at the 7th international conference on HHV-6 & 7.
Three new studies suggest a link between HHV-6 and epilepsy
Research groups in China, Germany and the US each publish compelling evidence that HHV-6 plays a role in epilepsy.
HHV-6 Reactivation after Transplantation
Researchers at Seattle Children’s Hospital found HHV-6 infection coupled with delirium and neurocognitive decline in 35% of patients after hematopoietic cell transplantation.